The Non-Financial Ledger

Addiction is one of the most desperate places a person can find themselves. You aren’t looking for a luxury experience when you walk into a clinic trying to get clean (or rather, most sane people aren’t). You are looking for someone who knows what they are doing, who has the legal authority to help you, and who cares whether you live or die. The patients who came to Novel Psychopharmacology came with that kind of trust.

What the trial record shows is that they received something else. Former students interning at the clinic testified to performing implant procedures in a room described as dark and dirty, with sterilization shortcuts that no medical setting should tolerate: expired anesthetic, sterile drapes that had already been opened and reused, conditions that a former receptionist said made it impossible for the space to have been sterile because patients cycled through it all day with no one going back in to clean before the next procedure began.

One former patient testified that she waited twelve hours to see the doctor. Another described feeling like she was being sold something rather than treated. She had seen addiction specialists before; she knew what a collaborative doctor-patient relationship felt like, and this was not it. She relapsed after treatment. She was not alone in that outcome.

The implants placed inside these patients’ bodies were not FDA-approved formulations. The FDA approves specific forms of medications for specific reasons. Naltrexone in tablet and injectable form had been reviewed, tested, and cleared. The pellet implant version had not. No one had established, through the safety review process that exists precisely for situations like this, whether implanting that formulation was safe, whether the dosing was accurate, whether the body would absorb it correctly, or what the failure modes were.

What the jury heard was that at least ten patients suffered documented medical complications. An expert witness testified about the risks created by the conditions described: septic shock and death. These patients were not abstractions in a regulatory filing. They came to a clinic run by a licensed psychiatrist, trusted the medical framing of what was happening to them, and left with foreign objects in their bodies whose safety had never been established by the agency Congress created to answer exactly that question.

The mislabeled shipping boxes were the legal hook. The patients in that room were the actual story.

Legal Receipts

These are direct statements from the appellate record. They are not paraphrases.

“In each instance, a package was shipped into the United States. Each package contained the relevant items but was accompanied by shipping documents and a packing slip that described the contents as ‘plastic beads in plastic tubes’ and misstated the value of the contents of the package.”

• This establishes the core smuggling mechanism: every single shipment of unapproved drug implants entering the United States under Shafa’s watch was accompanied by customs documentation that was false on its face, both as to what was inside the package and what it was worth.
• This is what made the importation “contrary to law” under 18 U.S.C. § 541, which criminalizes the entry of falsely classified goods, in addition to the FDCA misbranding violation.
• Three separate shipments are documented: on or about June 30, 2016 (naltrexone pellet implants); on or about November 17, 2017 (more naltrexone pellet implants, naltrexone injections, and disulfiram pellet implants); and on or around January 3, 2018 (more disulfiram pellet implants).

“The government argues… that the District Court ‘reasoned’ that ‘the only way Shafa was shown to have imported the implants’ was ‘through the use of false Customs declarations’ and thus that it found that ‘the jury in finding the importations also found the fraud.'”

• This is the government’s sentencing argument, not a finding the appellate court accepted as settled. The First Circuit’s entire remand on the fraud guideline issue turns on the fact that the District Court never explicitly stated this reasoning, and the record does not compel it as the only possible interpretation.
• The practical consequence: the fraud guideline drove a 12-level sentencing enhancement, adding roughly three to five years of prison exposure to Shafa’s Guidelines range. Whether that enhancement survives remand depends on clarifications the District Court must now make.

“After presiding over the entirety of the Defendant’s trial, and for the reasons stated on the record at the Part I hearing, the [District Court] finds by a preponderance of the evidence that Dr. Shafa engaged in fraudulent conduct that establishes, in whole or in part, the instant offenses of his conviction.”

• The First Circuit found this statement insufficient to resolve the sentencing ambiguity. The District Court did not specify what the fraudulent conduct was, which offense it “established,” or how it interacted with the conduct for which Shafa had been acquitted.
• This is why the case was remanded: not because the sentence was too harsh, but because the legal reasoning underlying it was not stated clearly enough to survive appellate review.

“The District Court pointed to ‘the testimony of Agent Roy,’ who stated that the investigation began in 2008, in support of the finding that ‘the time period alleged in the indictment for the offenses of conviction’… was January 2008 through January 2018.”

• This is the evidentiary basis for counting nearly a decade of conduct in Shafa’s sentencing. The District Court did not limit its view of the offense to the three charged shipments in 2016-2018.
• A 2009 email, read into the record by Agent Roy, showed Moran asking Shafa whether to “send by courier again” and noting he had not shipped to the United States “since the last time that [Shafa’s] shipment was held up.” The First Circuit found it was not clear error to treat this as evidence of earlier uncharged shipments.

“Where a product has a value of zero as a matter of law, but consumers pay for the product as if it had value, the buyers have been robbed of the benefit of their bargain.”

• This is the legal standard the First Circuit applied to affirm the loss calculation exceeding $250,000. Because the drug formulations were unapproved and therefore had zero legal value, every dollar a patient paid counted as a loss under the fraud guideline’s sentencing table.
• This drove the 12-level upward adjustment to Shafa’s offense level and is one of the most consequential findings in the entire sentencing analysis.

Public Deception

Shafa’s own attorney framed his defense to the jury as the story of a dedicated doctor up against a bureaucratic agency. The trial record shows the gap between that framing and the documented facts.

• Claim: Shafa was described to the jury in opening statement as “a doctor, an MD, dedicated to eradicating the scourge of opioid addiction” fighting against “the Food and Drug Administration’s efforts to stop him.” Reality documented at trial: The clinic performed implant procedures in conditions that former interns and a receptionist described as unsanitary, including previously-opened sterile drapes, expired anesthetic, no room sterilization between patients, and what one expert said created a “significantly higher likelihood of causing an infection.”
• Claim: The shipping packages were labeled “plastic beads in plastic tubes.” Reality documented at trial: The packages contained naltrexone pellet implants and disulfiram pellet implants ordered from a doctor in Hong Kong and intended for surgical implantation in patients. The label was deliberately false. The dollar value on the customs documents was also false.
• Claim: Shafa argued at sentencing that his patients benefited from the treatment they received and that therefore the fees they paid should not count as “loss.” Reality under federal law: The First Circuit affirmed that because the drugs were unapproved and therefore had zero legal value, patients were “robbed of the benefit of their bargain” regardless of any perceived therapeutic effect. The loss exceeded $250,000.

Profit-Maximization at All Costs

The sentencing record shows that Shafa collected patient fees for a service he had no legal authorization to provide, using products he had to smuggle across international borders to obtain.

• The FDA had approved tablets containing disulfiram and tablets and injectable liquids containing naltrexone. It had not approved naltrexone pellet implants, disulfiram injections, or disulfiram pellet implants. Shafa ordered and imported all three unapproved formulations anyway, from a doctor in Hong Kong named Wayne Moran.
• The total documented patient fees for treatments involving these misbranded drugs was found by the District Court to exceed $250,000, triggering a 12-level upward enhancement under the fraud guideline’s loss table. This figure drove Shafa’s recommended sentencing range from a base of 6 levels to a calculated total offense level of 26, producing a Guidelines range of 63 to 78 months.
• The First Circuit affirmed the $250,000-plus loss figure under established precedent holding that where a product has zero legal value, every dollar collected for it constitutes loss. Shafa’s argument that patients actually benefited was legally irrelevant to this calculation.
• The sentencing record also reflects uncharged conduct extending back to at least 2008, based on a 2009 email in which Moran referenced sending shipments by courier and noted he had not shipped to the U.S. “since the last time that [Shafa’s] shipment was held up.” The District Court found this indicated the arrangement was ongoing for roughly a decade.
• Shafa was sentenced to 36 months on each count, all concurrent, a significant downward variance from the 63-to-78-month Guidelines range. The First Circuit retained jurisdiction and remanded for clarification of the fraud guideline application; depending on what the District Court clarifies, his sentencing exposure may shift.

How Delay Enabled a Decade of Unapproved Implants

The sentencing record indicates the scheme ran for roughly ten years before federal charges were brought, and the timeline of how long it continued before accountability arrived is part of the documented record.

• A 2009 email entered into evidence at the sentencing phase shows Moran asking Shafa whether to “send by courier again” and noting a previous shipment had been “held up.” The First Circuit found this email was “clearly not the first communication” between the two, placing the origin of the arrangement before 2009.
• The superseding indictment was handed up on July 8, 2021, following an earlier indictment. The conduct charged in the convictions spans June 2016 through January 2018, but the District Court’s sentencing window ran from January 2008 through January 2018, a span of ten years.
• Trial began on January 23, 2024. Sentencing occurred on December 16, 2024. The appellate decision was issued April 24, 2026. From the documented start of the arrangement in 2008 to a final settled sentence, the legal process spans at least 17 years of elapsed time.

The Supplier Arrangement: Wayne Moran and the Hong Kong Pipeline

The structure of the drug supply chain in this case placed a foreign doctor at the center of the importation, creating a layer of distance between Shafa and the actual manufacture and repackaging of the unapproved formulations.

• Wayne Moran was a doctor based in Hong Kong. According to testimony from the Gooberman trial (a parallel federal case involving another American doctor who also imported naltrexone pellets), Moran purchased pellets from others, conveyed them to a medical storage facility in Hong Kong named United Mail Order, repackaged and labeled them, and then shipped them to patients in multiple countries. Moran was Shafa’s supplier.
• Moran instructed United Mail Order to describe the products as “plastic beads and plastic tubes” rather than naltrexone pellets on shipping labels, according to his testimony in the Gooberman trial. That testimony was excluded from Shafa’s trial, meaning the jury that convicted Shafa never heard Moran’s own explanation for why the labels were false.
• The exclusion of Moran’s testimony was central to Shafa’s defense: he argued that Moran, not Shafa, had devised the false labeling. The First Circuit upheld the exclusion on multiple grounds. The defense theory was disputed but the underlying structural point stands: the arrangement involved at least three entities (Shafa’s clinic, Moran, United Mail Order) across two countries, and each layer added distance from the final product.
• Shafa was nonetheless convicted on the importation and money laundering counts because, as the customs specialist testified, federal law places responsibility for the accuracy of shipping declarations on the importer, which was Shafa.

Societal Impact Mapping

Public Health

The documented harms to patients are specific, physical, and ongoing at the time of trial.

• At least ten patients suffered medical complications from the implants, according to the government’s victim list at sentencing. This number was accepted by the First Circuit as legally sufficient to trigger the “ten or more victims” sentencing enhancement under the Guidelines.
• Former interns testified that procedures were performed without adequate sterile technique: previously-opened sterile drapes, no room decontamination between patients, insufficient hand-washing and personal protective equipment. An expert witness testified this created a “significantly higher likelihood of causing an infection” and invoked the risk of “septic shock and death.”
• The FDA approves specific drug formulations specifically because untested forms of a drug can have different absorption rates, dosing accuracy, or failure modes. Naltrexone pellet implants had not cleared that review. Patients receiving these implants had no way to know whether the dosing was accurate, how the formulation would behave inside their bodies, or what the long-term consequences were.
• Several patients testified to relapsing after treatment. The causal relationship between the unapproved formulation and treatment failure cannot be established from this record alone, but the documented existence of ten or more patients with complications and multiple relapses is part of the trial record.
• Former patient testimony described waiting up to twelve hours to see the physician, and feeling “like she was being sold something” rather than receiving clinical care. This context is relevant to how these patients experienced what was presented to them as legitimate medical treatment.

Economic Inequality

The people most likely to seek addiction treatment at a small clinic charging cash or insurance fees for implant procedures are not people with unlimited medical options. The economic dimension of this case runs through every part of it.

• The loss figure of over $250,000 represents fees paid by patients for treatments that had zero legal value under federal law. These were not elective luxury purchases. People seeking addiction treatment are frequently in financial distress. Every dollar paid was a dollar spent under the assumption that the treatment was legitimate.
• The sentencing record covers a period the District Court placed from 2008 to 2018. Patients treated across that decade had no practical mechanism to know that the formulations they were receiving were unapproved; the clinic was operated by a licensed psychiatrist, the treatments were framed as medical procedures, and the supply chain was deliberately obscured through false shipping documents.
• The patients who relapsed did not receive refunds. The patients who suffered complications bore their own medical costs for treating those complications. The $250,000-plus in recovered loss figures in the sentencing calculation do not appear to have been redistributed to the patients themselves; this was a criminal prosecution, not a class action.

The Sentence Is Not the End of This Story

Shafa received 36 months concurrent on all seven counts: a substantial downward variance from the 63-to-78-month Guidelines range. The First Circuit has now sent the case back for further proceedings that could change that number. Here is what the sentencing record leaves unresolved.

• The 36-month sentence is concurrent, meaning Shafa serves the same time for all seven convictions that he would serve for one. Three counts of international money laundering and three counts of unlawful importation carry the same prison exposure in practice as a single misdemeanor conviction in this case.
• The entire 12-level sentencing enhancement that pushed the Guidelines range to 63-78 months is now under review on remand. If the District Court cannot articulate a sufficient basis for applying the fraud guideline consistent with the acquitted-conduct amendment, that enhancement could be removed, lowering the recommended range and potentially the sentence itself. The First Circuit retained jurisdiction; it has not closed this appeal.
• The sentence for misdemeanor misbranding was vacated outright because the District Court imposed 36 months when the statutory maximum for that specific offense is 12 months. This was an error the government conceded. It is a narrow technical correction, but it illustrates that the sentencing phase of this case contained errors that required appellate intervention.
• There is no indication in this record that the patients who were harmed received any financial restitution. The criminal prosecution established guilt and imposed a prison term; it did not appear to produce a compensatory outcome for the people who paid for unapproved implants and suffered documented complications.
• Wayne Moran, the Hong Kong supplier who provided the unapproved formulations and instructed the use of false shipping labels, is referenced throughout this case but was not a defendant in this proceeding. His testimony was excluded from Shafa’s trial. His own legal accountability, if any, is outside the scope of this record.

This Is the System Working as Intended

The specific facts of this case illustrate how the gap between regulatory approval and market access can be monetized at the expense of patients who have no way to close that gap themselves.

• FDA drug approval is a process that takes years and costs money. That process does not directly benefit individual clinicians who want to offer unapproved formulations now. The documented incentive structure in this case was: import what is not approved, charge full price as though it were, absorb the difference as profit. The patients paid for the regulatory shortcut without knowing they were subsidizing it.
• The false customs documentation was not incidental to the scheme; it was the mechanism that made it sustainable. Every shipment from 2016 to 2018 was falsely labeled. The 2009 email suggests this practice predated the charged conduct by years. The customs system was gamed not once but repeatedly over a documented decade.
• The FDA approves specific drug forms, not just active ingredients, because form matters. Tablets, injectables, and pellet implants have different pharmacokinetic profiles. The approval process for each form exists because “this active ingredient works” does not mean “this delivery mechanism is safe.” Bypassing that process for a decade while charging patients for the results is precisely what the FDCA’s criminal provisions were designed to address.
• The jury acquitted Shafa’s wife of all counts. It acquitted Shafa himself on several counts, including the conspiracy charges. It found he acted without intent to defraud on the misbranding count, reducing it to a misdemeanor. The result is seven felony-level convictions on seven counts with a 36-month concurrent sentence and a case still on remand. Whether that outcome is proportionate to a scheme the District Court found ran from 2008 to 2018, involving ten or more documented victims and over $250,000 in patient fees, is a question this record raises without answering.

What a Legitimate Fix Looks Like

This case exposes two specific structural failures: the ease with which unapproved drug formulations can be smuggled through customs via falsified documentation, and the absence of any compensatory mechanism for patients harmed by unlicensed medical procedures.

Regulatory Track

• Customs enforcement for medical imports: The documented use of “plastic beads in plastic tubes” as a cover description for surgical implants over multiple years and multiple shipments points to a gap in customs screening for small packages containing medical devices and drug formulations. The FDA and U.S. Customs and Border Protection should establish coordinated screening protocols specifically for packages routed to medical clinic addresses, where the risk of drug importation is documentably higher.
• Mandatory adverse event reporting for compounding and unapproved formulations: Patients receiving any treatment involving a compounded or unapproved drug formulation should be tracked through a mandatory, centralized adverse event registry. The ten documented complications in this case were surfaced only through criminal prosecution. A proactive registry would surface harm earlier.
• Patient notification requirements: Any clinic offering a treatment involving a non-FDA-approved formulation should be required by law to provide written disclosure to patients explaining the approval status of the specific formulation being used, not just the active ingredient. “This active ingredient is FDA-approved” is not the same as “this formulation is FDA-approved.” That distinction should be legally required to be communicated in plain language.

Legislative Track

• Criminal restitution to patients: The current criminal prosecution framework produced a prison sentence but no documented financial restitution to the ten or more patients who suffered complications or the broader patient population that paid over $250,000 for treatments that had zero legal value. Mandatory restitution orders tied to criminal loss calculations should be standard in FDCA cases involving patient harm.
• Strengthened liability for importers of misbranded drugs: 18 U.S.C. § 545 and the FDCA together established the legal basis for this prosecution, but the case also illustrates that a decade of violations can occur before charges are brought. Statute of limitations reform for ongoing FDCA violations involving patient harm would allow prosecution of the full documented course of conduct rather than only the charged shipments.

Corporate Governance Track

• Independent clinical oversight for single-physician clinics: Novel Psychopharmacology was owned and operated by Shafa, with his wife as manager. No independent clinical oversight body was documented in this record as having flagged the unapproved formulations or the sanitation conditions described at trial. State medical licensing boards should require periodic third-party audits of single-physician clinics offering surgical procedures, with particular scrutiny for any clinic using formulations not available through standard pharmaceutical distribution channels.
• Supply chain transparency for clinic procurement: Any medical clinic performing implant or injection procedures should be required to document the regulatory approval status of every substance being implanted or injected, including the specific formulation and its country of origin. That documentation should be accessible to state regulators without requiring a federal criminal investigation to surface it.

What Now?

The entities responsible for the documented harms in this case include the operator of Novel Psychopharmacology, now a convicted federal felon, and the regulatory and legal systems that allowed the arrangement to run for approximately a decade before producing charges.

Watchlist: Agencies with Jurisdiction Over the Issues in This Case

• FDA (Food and Drug Administration): The primary federal body responsible for drug approval and enforcement of the FDCA. The misbranding and unlawful importation convictions in this case are core FDA jurisdiction. If you are a patient who received unapproved drug formulations from any clinic, you can file a MedWatch adverse event report at fda.gov.
• DOJ (Department of Justice): The prosecuting authority in this case. The case remains active on remand to the District of Massachusetts. Sentencing outcomes in FDCA cases are public record and worth tracking.
• U.S. Customs and Border Protection: The agency responsible for detecting falsely classified imports. The documented use of false customs declarations over multiple years is a documented gap in CBP enforcement that falls within its remit to address.
• State Medical Licensing Boards (Massachusetts Board of Registration in Medicine): State licensing boards have authority over physician conduct independent of federal criminal conviction. A federal conviction for conduct related to medical practice triggers mandatory review in most states.

Grassroots and Mutual Aid

• If you or someone you know received treatments at Novel Psychopharmacology: Document everything. Medical records, billing records, any communications from the clinic. A criminal conviction does not automatically produce civil relief; a civil attorney specializing in medical malpractice or consumer fraud can advise on whether a claim is viable.
• Harm reduction organizations: If you or someone you know is seeking addiction treatment, organizations such as the Substance Abuse and Mental Health Services Administration (SAMHSA) maintain a treatment locator at findtreatment.gov that lists only licensed, FDA-compliant treatment providers. The presence of a board-certified physician does not guarantee that all treatments offered are FDA-approved.
• Push for patient restitution reform: Contact your federal representatives to advocate for mandatory restitution orders in FDCA criminal cases involving documented patient harm. The patients in this case are not named in the appellate record. They absorbed the financial and physical costs of this scheme. The criminal sentence did not make them whole.